

27 Sep 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Novartis gives back Beigene PD-1; BMS revs R&D engine; Anthos changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2's top-selling drugs.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 22 September 2023, including: [Novartis AG](#) gives back [BeiGene, Ltd.](#) PD-1; [Bristol Myers Squibb Company](#) revs R&D engine; [Anthos Therapeutics Inc.](#) changes course for Factor XI asset; the non-incretin pipeline for obesity; and a look at Q2's top-selling drugs.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Novartis Drops BeiGene PD-1 Asset Tevimbra As Drug Wins Esophageal Cancer Nod In Europe](#)" - Scrip, 19 Sep, 2023.)

(Also see "[BMS Revs R&D Engine To Advance 10 New Drug Candidates Annually](#)" - Scrip, 15 Sep, 2023.)

(Also see "[Anthos Changing Course With Factor XIa Inhibitor, Targeting Atrial Fibrillation Patients First](#)" - Scrip, 18 Sep, 2023.)

(Also see "[Taking On Obesity The Hard Way](#)" - Scrip, 20 Sep, 2023.)

(Also see "[Top 10 Best-Selling Drugs Of Q2 2023: COVID-19 Out, HPV In](#)" - Scrip, 19 Sep, 2023.)

[Click here to explore this interactive content online](#) ✨